The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.
Ablynx NV (ABLX) : The Belgian developer of drugs based on antibodies found in llamas said “two serious adverse events” occurred during a mid-stage study of an experimental treatment for a rare blood disorder known as TTP, without elaborating. Patient recruitment for the study continues. Ablynx shares dropped 2.3 percent to 7.77 euros.
Bekaert NV (BEKB BB): The world’s largest maker of steel cord used in tires may say first-half net income rose 3 percent to 186.5 million euros ($267 million), the average estimate of four analysts surveyed by Bloomberg. Bekaert shares fell 3.6 percent to 48.195 euros.
Belgacom SA (BELG) : The largest telephone company in Belgium said an internal probe showed the company’s interests were fully protected after Chief Executive Officer Didier Bellens informed directors that he was indicted for passive private corruption in a judicial investigation of a real-estate transaction in 2005. Belgacom also is scheduled to report second-quarter earnings. The shares retreated 0.3 percent to 23.57 euros.
Colruyt NV (COLR BB): Belgium’s largest discount food retailer said fiscal first-quarter revenue rose 8.9 percent to 1.95 billion euros. The shares advanced 0.3 percent to 34.10 euros.
Exmar NV (EXM) : The operator of the world’s largest fleet of midsize gas tankers hauling liquefied petroleum gas and ammonia posted a narrower first-half net loss of $35.4 million compared with a loss of $45.9 million in the year-earlier period. The shares lost 4.3 percent to 5.15 euros.
Telenet Group Holding NV (TNET) : The Belgian cable operator controlled by Liberty Global Inc. said second-quarter net income rose to 15.7 million euros and raised its full-year sales forecast to as much as 1.38 billion euros after revenue growth accelerated for the first time in almost two years. Telenet shares fell 0.7 percent to 28.80 euros before trading was halted at about 5:12 p.m. in Brussels.
UCB SA (UCB) : The maker of the Cimzia arthritis drug may report first-half profit excluding some items of 1.07 euros a share, according to the average of 11 analyst estimates compiled by Bloomberg. UCB shares rose 0.3 percent to 32.48 euros.